Onco-Innovations Ltd. ONNVF Archives

TuesdaySep 08, 2026 11:15 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Builds Manufacturing, IND and Capital Foundation Ahead of Planned Clinical Translation

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Investors in biotechnology often look for companies with a clear path toward clinical development, where regulatory preparation, manufacturing readiness and access to capital can help reduce execution risk. Onco-Innovations Ltd. is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company has strengthened its clinical foundation through manufacturing milestones, IND-enabling activities, strategic partnerships and a recent funding arrangement designed to support continued advancement of its oncology pipeline. For biotechnology investors, a…

FridaySep 04, 2026 9:00 am

From Molecule to Medicine: Onco-Innovations Aligns ONC010 for Clinical Development

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations has advanced ONC010 across API manufacturing, polymer optimization, analytical development, preclinical characterization and clinical planning as it works toward human evaluation. A 300-gram development batch of ONC010's active ingredient achieved approximately 99.3% purity, while a newly identified non-tin catalyst could support improved control of impurities in future polymer manufacturing. The company is building an Australian pathway for a potential First-in-Human study while advancing bioanalytical, metabolism, ADME, toxicology, biodistribution and regulatory preparation during the second half of 2026. Cancer therapies built around…

FridayAug 14, 2026 3:05 pm

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Builds Foundation for Biomarker-Driven Cancer Therapy

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing its precision oncology strategy through ONC010, a nanoparticle-encapsulated PNKP inhibitor being developed for biomarker-selected cancers. The company is building the manufacturing and scientific foundation needed to advance the program toward first-in-human studies, including polymer process development and analytical characterization activities with Nanosoft Polymers and metabolism studies through Nucro-Technics as part of its IND-enabling program. These efforts are designed to support scalable manufacturing, characterize ONC010’s metabolic profile and generate data for future pharmacokinetic, toxicology and regulatory activities. By combining targeted PNKP inhibition, nanoparticle…

WednesdayAug 05, 2026 1:15 pm

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Combines Targeted Cancer Therapy, Nanotechnology and AI

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is pursuing an integrated approach to cancer drug development that combines three emerging areas: PNKP-targeted DNA damage response (“DDR”) inhibition, nanoparticle drug delivery and artificial intelligence. Its lead candidate, ONC010, pairs a PNKP inhibitor with a polymer micelle carrier intended to improve drug solubility, tumor accumulation and tolerability, while the company’s Inka Health subsidiary is developing the SynoGraph causal AI platform to support patient selection, clinical trial design and evidence generation. The company is advancing ONC010 through preclinical, manufacturing and IND-enabling…

MondayJul 27, 2026 2:53 pm

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Moves Lead Oncology Candidate Toward Future Clinical Studies

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing the development of its lead oncology candidate, ONC010, a PNKP inhibitor designed to disrupt cancer cells’ DNA repair mechanisms and potentially address treatment resistance. The company recently advanced kilogram-scale manufacturing of a key precursor used to produce ONC010’s active pharmaceutical ingredient, supporting future formulation development, GMP production and clinical studies. Onco-Innovations also signed a letter of intent with Nanosoft Polymers to advance polymer development, drug delivery optimization and formulation work, while engagements with Nucro-Technics and Avance Clinical support bioanalytical development and clinical…

MondayJul 27, 2026 9:00 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Combining Three Emerging Frontiers in Cancer Drug Development

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. As precision oncology becomes increasingly dependent on biomarker-driven therapies, smarter clinical trial design, and advanced drug delivery technologies, companies capable of integrating may be better positioned to address some of oncology's most persistent development challenges. Onco-Innovations pairs a PNKP inhibitor, a DDR target distinct from PARP, with a nanoparticle delivery system in its lead candidate ONC010, and adds AI through its Inka Health subsidiary and the SynoGraph causal AI platform Onco-Innovations is advancing ONC010 through IND-enabling, manufacturing, and regulatory work, while using AI-enabled tools intended to support…

ThursdayJul 23, 2026 10:30 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Advances Precision Oncology as Biomarker-Driven Cancer Gains Momentum

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. ONC010 is being developed for biomarker-selected cancers, aligning with the growing shift toward precision medicine The company is currently advancing ONC010 through manufacturing, and IND-enabling development programs Onco-Innovations combines targeted therapeutics, nanoparticle drug delivery, and AI-native discovery to address treatment-resistant cancers Cancer treatment is undergoing one of its most significant transformations in decades. Rather than relying on the traditional “one drug fits all” approach, oncology is increasingly embracing precision medicine. This strategy uses genomic testing and biomarker analysis to identify patients most likely to benefit from specific…

MondayJul 13, 2026 9:10 am

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Completes Analytical Reference Standard Program for ONC010

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient supporting its lead oncology candidate, ONC010. Completed in collaboration with Dalton Pharma Services, the program established a qualified reference standard to support analytical testing, manufacturing consistency, quality control and future regulatory and clinical activities. The milestone strengthens the company's chemistry, manufacturing and controls ("CMC") framework and follows recent progress in API manufacturing, precursor scale-up, analytical method development and chiral purity testing. Onco-Innovations…

WednesdayJul 01, 2026 9:30 am

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Announces Term Sheet for CAD$5 Million Private Placement

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced it has executed a term sheet with arm's-length institutional investors for a previously announced non-brokered private placement with a notional subscription amount of approximately CAD$5 million. The offering will consist of 6,764,070 units at a notional price of CAD$0.7392 per unit, with each unit comprising one common share and one common share purchase warrant, and is expected to close on or about July 15, 2026, subject to customary conditions and regulatory approvals. The company said proceeds from the…

WednesdayJul 01, 2026 9:00 am

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Advances ONC010 Manufacturing Development With Nanosoft

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced the initiation of polymer process development and analytical characterization activities by Nanosoft Polymers in support of ONC010, the company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase inhibitor. The work includes polymer synthesis optimization, characterization methodology development, molecular weight assessment, purification strategy refinement and manufacturing scalability assessments as part of Onco-Innovations' chemistry, manufacturing and controls strategy. The company said the activities are intended to establish a scalable, reproducible and analytically characterized polymer platform to support future formulation, manufacturing, regulatory and clinical…

Site Search

Company Search

Tag: Onco-Innovations Ltd. ONNVF